Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-common hematologic malignancy. Despite advances in therapy, MM remains largely incurable. Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, which is highly expressed on myeloma cells, and the antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Kerry S., Cohen, Adam D., Pazina, Tatiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230619/
https://www.ncbi.nlm.nih.gov/pubmed/30455698
http://dx.doi.org/10.3389/fimmu.2018.02551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230619/
https://www.ncbi.nlm.nih.gov/pubmed/30455698
http://dx.doi.org/10.3389/fimmu.2018.02551

Ejemplares similares